Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21361272 | 0.92 | ALDH1A1 (0.38) | CHRM4CHRM1CHRM2CHRM5HDAC2 | |
| SCHEMBL21361303 | 0.87 | CYP2D6 (0.41) | HDAC2HDAC1ALDH1A1HDAC3ROCK2 | |
| SCHEMBL21361258 | 0.85 | HDAC2 (0.35) | HDAC2HDAC1MEN1ALDH1A1MAPT | |
| SCHEMBL21361273 | 0.85 | HDAC2 (0.37) | HDAC2HDAC1MEN1ALDH1A1MAPT | |
| SCHEMBL21361254 | 0.84 | RORC (0.40) | HDAC2HDAC1MEN1ALDH1A1KMT2A | |
| SCHEMBL21361260 | 0.84 | CYP2D6 (0.45) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21361274 | 0.84 | HDAC2 (0.34) | HDAC2HDAC1ALDH1A1 | |
| SCHEMBL21361284 | 0.83 | HDAC2 (0.37) | HDAC2HDAC1ALDH1A1GRIN2B | |
| SCHEMBL21361271 | 0.83 | CYP2D6 (0.46) | MEN1ALDH1A1KMT2A | |
| SCHEMBL24120294 | 0.83 | CHRM4 (0.40) | CHRM4CHRM1CHRM2CHRM5HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765445-B1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019175117-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | CBR3, DDT, CBR1 | CHRM4 1003/4885CHRM1 416/4885CHRM2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.